Multiparametric technologies for the diagnosis of syndromic infections

Clinical Microbiology Newsletter

Volumn 34, Issue 20, 2012, Pages 159-168

  Bissonnette, Luc ^a   Bergeron, Michel G ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; ESCHERICHIA COLI; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIAL IDENTIFICATION; MICROBIOLOGICAL PARAMETERS; MICROFLUIDIC ANALYSIS; MOLECULAR DIAGNOSIS; MOLECULAR HYBRIDIZATION; MORTALITY; MULTIPARAMETRIC DETECTION; MULTIPLEX REAL TIME POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; SEPSIS; URINALYSIS; URINARY TRACT INFECTION;

EID: 84867087398     PISSN: 01964399     EISSN: 18734391     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2012.09.003     Document Type: Article

References (54)

1. Lehmann L.E., et al. Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials. Crit. Care 2010, 14:R186.
2. Kumar A., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248.
3. Lin J.-N., et al. Characteristics and outcomes of polymicrobial bloodstream infections in the emergency department: a matched case-control study. Acad. Emerg. Med. 2010, 17:1072-1079.
4. Micek S.T., Reichley R.M., Kollef M.H. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine 2011, 90:390-395.
5. Nicolau D.P. Current challenges in the management of the infected patient. Curr. Opin. Infect. Dis. 2011, 24(Suppl.1):S1-S10.
6. Jabes D. The antibiotic R&D pipeline: an update. Curr. Opin. Microbiol. 2011, 14:564-569.
7. Griffith M.M., et al. The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. Clin. Infect. Dis. 2012, 54:684-691.
8. Klotz S.A., et al. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn. Microbiol. Infect. Dis. 2007, 59:401-406.
9. Rogers G.B., et al. Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy. Trends Microbiol. 2010, 18:357-364.
10. Schimke I. Quality and timeliness in medical laboratory testing. Anal. Bioanal. Chem. 2009, 393:1499-1504.
11. Bissonnette L., Bergeron M.G. The next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine. Expert Rev. Mol. Diagn. 2006, 6:433-450.
12. Association for Molecular Pathology. FDA-cleared/approved molecular diagnostics tests. (last accessed February 2012). http://www.amp.org/FDATable/FDATable.doc.
13. McGeer A. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 2007, 45:1568-1575.
14. Bissonnette L., Bergeron M.G. Diagnosing infections - current and anticipated technologies for point-of-care diagnostics and home-based testing. Clin. Microbiol. Infect. 2010, 16:1044-1053.
15. Cohen-Bacrie S., et al. Revolutionizing clinical microbiology laboratory organization in hospitals with in situ point-of-care. PLoS One 2011, 6:e22403.
16. Daniels R. Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective). J. Antimicrob. Chemother. 2011, 66:ii11-ii23.
17. Ecker D.J., et al. New technology for rapid molecular diagnosis of bloodstream infections. Expert Rev. Mol. Diagn. 2010, 10:399-415.
18. Paolucci M., Landini M.P., Sambri V. Conventional and molecular techniques for the early diagnosis of bacteraemia. Int. J. Antimicrob. Agents 2010, 36S:S6-S16.
19. Endimiani A., et al. Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?. Clin. Infect. Dis. 2011, 52(Suppl. 4):S373-S383.
20. Pavia A.T. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin. Infect. Dis. 2011, 52(S4):S284-S289.
21. Infectious Diseases Society of America An unmet need: rapid molecular diagnostics tests for respiratory tract infections. Clin. Infect. Dis. 2011, 52(S4):S384-S385.
22. Foxman B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 2010, 7:653-660.
23. Imirzalioglu C., et al. Hidden pathogens uncovered: metagenomic analysis of urinary tract infections. Andrologia 2008, 40:66-71.
24. Goff D.A. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr. Opin. Infect. Dis. 2011, 24(Suppl.1):S11-S20.
25. Umscheid C.A., et al. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect. Control Hosp. Epidemiol. 2011, 32:101-114.
26. Brown J., Paladino J.A. Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia. Pharmacoeconomics 2010, 28:567-575.
27. Avolio M., et al. Molecular identification of bloodstream pathogens in patients presenting to the emergency department with suspected sepsis. Shock 2010, 34:27-30.
28. Obara H., et al. The role of real-time PCR technology for rapid detection and identification of bacterial and fungal pathogens in whole-blood samples. J. Infect. Chemother. 2011, 17:327-333.
29. grade in detecting microbial pathogens in purulent fluids. J. Clin. Microbiol. 2011, 49:2988-2991.
30. Tissari P., et al. Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet 2010, 375:224-230.
31. Jordan B.R. Is there a niche for DNA microarrays in molecular diagnostics?. Expert Rev. Mol. Diagn. 2010, 10:875-882.
32. Balada-Llasat J.-M., et al. Evaluation of commercial ResPlex II v2.0, MultiCode®-PLx, and xTAG® respiratory viral panels for the diagnosis of viral infections in adults. J. Clin. Virol. 2011, 50:42-45.
33. Dundas N.E., et al. A lean laboratory - Operational simplicity and cost effectiveness of the Luminex xTAG® respiratory viral panel. J. Mol. Diagn. 2011, 13:175-179.
34. Dumonceaux T.J., et al. Multiplex detection of bacteria associated with normal microbiota and with bacterial vaginosis in vaginal swabs by use of oligonucleotide-coupled fluorescent microspheres. J. Clin. Microbiol. 2009, 47:4067-4077.
35. Landlinger C., et al. Species-specific identification of a wide range of clinically relevant fungal pathogens by use of Luminex xMAP technology. J. Clin. Microbiol. 2009, 47:1063-1073.
36. Platts-Mills J.A., Operario D.J., Houpt E.R. Molecular diagnosis of diarrhea: current status and future potential. Curr. Infect. Dis. Rep. 2012, 14:41-46.
37. Emonet S., et al. Application and use of various mass spectrometry methods in clinical microbiology. Clin. Microbiol. Infect. 2010, 16:1604-1613.
38. Ferroni A., et al. Real-time identification of bacteria and Candida species in positive blood culture broths by matrix-assisted laser desorption ionization-time of flight spectrometry. J. Clin. Microbiol. 2010, 48:1542-1548.
39. Seng P., et al. MALDI-TOF-mass spectrometry applications in clinical microbiology. Future Microbiol. 2010, 5:1733-1754.
40. La Scola B. Intact cell MALDI-TOF mass spectrometry-based approaches for the diagnosis of bloodstream infections. Expert Rev. Mol. Diagn. 2011, 11:287-298.
41. Kemp M., et al. Routine ribosomal PCR and DNA sequencing for detection and identification of bacteria. Future Microbiol. 2010, 5:1101-1107.
42. Jordan J.A., et al. Utility of pyrosequencing in identifying bacteria directly from positive blood culture bottles. J. Clin. Microbiol. 2009, 47:368-372.
43. Deng Y.-M., Caldwell N., Barr I.G. Rapid detection and subtyping of human influenza A viruses and reassortants by pyrosequencing. PLoS One 2011, 6:e23400.
44. Petrosino J.F., et al. Metagenomic pyrosequencing and microbial identification. Clin. Chem. 2009, 55:856-866.
45. Metzker M.L. Sequencing technologies - the next generation. Nat. Rev. Genet. 2010, 11:31-46.
46. Barnard R.T., Hall R.A., Gould E.A. Expecting the unexpected: nucleic acid-based diagnosis and discovery of emerging viruses. Expert Rev. Mol. Diagn. 2011, 11:409-423.
47. Brzuszkiewicz E., et al. Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: entero-aggregative-haemorrhagic Escherichia coli (EAHEC). Arch. Microbiol. 2010, 193:883-891.
48. Bainbridge M.N., et al. Whole-genome sequencing for optimized patient management. Sci. Transl. Med. 2011, 3:87re3.
49. Natrajan R., Reis-Filho J.S. Next-generation sequencing applied to molecular diagnostics. Expert Rev. Mol. Diagn. 2011, 11:425-444.
50. Mirnezami R., Nicholson J., Darzi A. Preparing for precision medicine. N. Engl. J. Med. 2012, 366:489-491.
51. Eicher D., Merten C.A. Microfluidic devices for diagnostic applications. Expert Rev. Mol. Diagn. 2011, 11:505-519.
52. Gibbs J.N. Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology. Expert Rev. Mol. Diagn. 2011, 11:367-381.
53. Russek-Cohen E., et al. FDA perspectives on diagnostic device clinical studies for respiratory infections. Clin. Infect. Dis. 2011, 52(S4):S305-S311.
54. Mitka M. Hospitalizations for extreme conditions mean extreme expenses, study verifies. JAMA 2010, 304:2579-2580.